StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) company profile

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$698.47+8.23 (+1.19%)

Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –

About IDEXX Laboratories

In Vitro & In Vivo Diagnostic Substances, SIC 2835

IDEXX Laboratories, Inc. develops, manufactures, and distributes diagnostic products and services primarily for companion animal veterinary care, livestock, poultry, dairy, and water testing. Operating through its Companion Animal Group, Water quality products, Livestock, Poultry and Dairy, and human diagnostics segments, the company serves veterinarians, biomedical researchers, livestock producers, water utilities, and diagnostic laboratories. Its offerings include point-of-care analyzers, consumables, rapid assays, reference laboratory services, practice management software, diagnostic imaging, and microbiological water tests.

The company maintains a commercial presence across North America, Europe, Asia Pacific, Latin America, and Africa. It operates a network of approximately 80 reference laboratories serving clients across countries including the United States, Canada, Australia, Japan, New Zealand, South Africa, and South Korea. IDEXX operates manufacturing and distribution facilities in Westbrook and Scarborough, Maine; Roswell, Georgia; Memphis, Tennessee; as well as the Netherlands, Switzerland, France, and the United Kingdom.

Summary of the business section of IDEXX Laboratories's latest annual report, written by StockData.

Company profile

Company

Legal name
IDEXX Laboratories Inc
Founded
1983
Headquarters
Westbrook, ME
Address
One Idexx Drive 04092-2041
Phone
(207) 556-0300
Employees
11,000, Dec 31, 2025
Industry
In Vitro & In Vivo Diagnostic Substances
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
IDXX
Exchange
Nasdaq
IPO date
Jun 21, 1991
Shares outstanding
79M, Jul 31, 2026
Public float
$42.90B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Jun 16, 2015; 2-for-1, Nov 27, 2007; 2-for-1, Jun 6, 1995; 2-for-1, Oct 4, 1993
SEC CIK
874716
CUSIP
45168D104
ISIN
US45168D1046
FIGI
BBG000BLRT07
Share class FIGI
BBG001S5S4Y9
LEI
OGMTXK0LUU1HKV2P0J84
EIN
01-0393723

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jonathan Jay MazelskyExecutive Chair of the Board, Director83,803
George FennellExecutive Vice President12,182
Michael LaneExecutive Vice President4,668
Sharon E. UnderbergEVP, GC & Corporate Secretary7,169
Andrew EmersonEVP, CFO and Treasurer4,507
Nimrata HuntExecutive Vice President18,301
Michael G. EricksonExecutive Vice President15,092
Michael Perkins JohnsonExecutive Vice President2,795
Martin Alexander SmithExecutive Vice President1,603
Michael SchreckExecutive Vice President2,123
Brian P. McKeonEVP, CFO and Treasurer49,600
Daniel M. JuniusDirector2,361
Joseph L. HooleyDirector373
Lawrence D. KingsleyDirector9,568
Irene Chang BrittDirector208
Bruce L. ClaflinDirector1,721
Sam SamadDirector0
Stuart EssigDirector2,236
Karen PeacockDirector102
Sophie V. VandebroekDirector9,078
M. Anne SzostakDirector2,320

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$14.58M$31.76M$3.06M$135$148
FY2024$13.01M$2.33M$3.77M$83$129
FY2023$11.52M$22.68M$3.31M$111$126
FY2022$9.79M-$13.75M$2.78M$82$124
FY2021$9.07M$28.21M$2.85M$132$126
FY2020$7.04M$34.87M$2.31M$191$113

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jonathan J. Mazelsky
President and Chief Executive Officer
$1.15M$5.40M$5.40M$2.59M$37.24K$14.58M+12%
Andrew Emerson
Executive Vice President and Chief Financial Officer
$531.15K$949.86K$949.94K$577.50K$24.62K$3.03M–
Michael J. Lane
Executive Vice President and General Manager, CAG Diagnostics Business Unit
$594.05K$1.35M$1.35M$627.27K$98.29K$4.02M+8%
Tina Hunt
Executive Vice President, Global Strategy and Commercial
$594.05K$1.35M$1.35M$627.27K$24.17K$3.95M+6%
Martin Smith
Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security
$594.05K$1.35M$1.35M$627.27K$23.41K$3.94M+6%
Brian P. McKeon
Former Executive Vice President, Chief Financial Officer and Treasurer
$293.40K–––$58.28K$351.68K-91%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 11,000 regular full-time and part-time employees in approximately 34 countries around the world, and men and women represented 41% and 59%, respectively, of our global employee population.”

Corporate history

Events identified from SEC filings

DateEventDetails
Feb 6, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)

See a number that looks wrong?